Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$25.17 USD
-1.18 (-4.48%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.16 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKRO 25.17 -1.18(-4.48%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
Other News for AKRO
venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
Akero Therapeutics Shares Cross Above 200 DMA
Optimistic Buy Rating for Akero Therapeutics Amidst Promising Efruxifermin (EFX) Developments
Wolfe Research starts Akero at outperform, cites MASH drug prospects